DAMPs activating innate and adaptive immune responses in COPD

Mucosal Immunology

Volumn 7, Issue 2, 2014, Pages 215-226

  Pouwels, S D ^a,b   Heijink, I H ^a,b   Ten Hacken, N H T ^b   Vandenabeele, P ^c,d   Krysko, D V ^c,d   Nawijn, M C ^a,b   Van Oosterhout, A J M ^a,b  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^c DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

^d GHENT UNIVERSITY   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; ADVANCED GLYCATION END PRODUCT RECEPTOR; ALPHA DEFENSIN; BETA DEFENSIN; CALRETICULIN; CATHELICIDIN; CATHELICIDIN ANTIMICROBIAL PEPTIDE LL 37; CELL PROTEIN; CIGARETTE SMOKE; FIBRONECTIN; FORMYLMETHIONINE; FORMYLPEPTIDE RECEPTOR; GALECTIN; GALECTIN 1; GALECTIN 3; HEAT SHOCK PROTEIN; HIGH MOBILITY GROUP B1 PROTEIN; HYALURONIC ACID; MITOCHONDRIAL DNA; MYELOID DIFFERENTIATION FACTOR 88; PROTEIN S 100; PURINERGIC P2X7 RECEPTOR; PURINERGIC P2Y2 RECEPTOR; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; VERSICAN;

ADAPTIVE IMMUNITY; APOPTOSIS; CHRONIC INFLAMMATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CYTOKINE RELEASE; DAMAGE ASSOCIATED MOLECULAR PATTERN; ENDOPLASMIC RETICULUM STRESS; HUMAN; INNATE IMMUNITY; LUNG EMPHYSEMA; LUNG FLUID; NECROPTOSIS; NEUTROPHIL CHEMOTAXIS; NEUTROPHILIA; NONHUMAN; PATHOGENESIS; PHAGOCYTOSIS; PRIORITY JOURNAL; RESPIRATORY TRACT INFLAMMATION; REVIEW; SMOKING;

ADAPTIVE IMMUNITY; ANIMALS; CARRIER PROTEINS; EXTRACELLULAR SPACE; HUMANS; IMMUNITY, INNATE; INTRACELLULAR SPACE; PROTEIN BINDING; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RECEPTORS, PATTERN RECOGNITION; SIGNAL TRANSDUCTION;

EID: 84895083345     PISSN: 19330219     EISSN: 19353456     Source Type: Journal    
DOI: 10.1038/mi.2013.77     Document Type: Review

References (148)

1. Halbert, R.J. et al. Global burden of COPD: Systematic review and metaanalysis. Eur. Respir. J. 28, 523-532 (2006).
2. World Health Organisation. WHO. World Health Statistics http:// www.who.int/whois/whostat/EN-WHS08-Full.pdf2008).
3. Barnes, P.J., Shapiro, S.D. & Pauwels, R.A. Chronic obstructive pulmonary disease: Molecular and cellular mechanisms. Eur. Respir. J. 22, 672-688 (2003).
4. Barnes, P.J. Immunology of asthma and chronic obstructive pulmonary disease. Nat. Rev. Immunol. 8, 183-192 (2008).
5. Brusselle, G.G., Joos, G.F. & Bracke, K.R. New insights into the immunology of chronic obstructive pulmonary disease. Lancet 378, 1015-1026 (2011).
6. Bruce, N., Perez-Padilla, R. & Albalak, R. Indoor air pollution in developing countries: A major environmental and public health challenge. Bull. World Health Organ. 78, 1078-1092 (2000).
7. O+Donnell, R., Breen, D.,Wilson, S. & Djukanovic, R. Inflammatory cells in the airways in COPD. Thorax 61, 448-454 (2006).
8. Cosio, M.G., Saetta, M. & Agusti, A. Immunologic aspects of chronic obstructive pulmonary disease. N. Engl. J. Med. 360, 2445-2454 (2009).
9. Gruffydd-Jones, K. GOLD guidelines 2011: What are the implications for primary care+ Prim. Care Respir. J. 21, 437-441 (2012).
10. Curtis, J.L., Freeman, C.M. & Hogg, J.C. The immunopathogenesis of chronic obstructive pulmonary disease: Insights from recent research. Proc. Am. Thorac. Soc. 4, 512-521 (2007).
11. Matzinger, P. Tolerance, danger, and the extended family. Annu. Rev. Immunol. 12, 991-1045 (1994).
12. Messner, B. et al. Apoptosis and necrosis: Two different outcomes of cigarette smoke condensate-induced endothelial cell death. Cell Death Dis. 3, e424 (2012).
13. Kaczmarek, A., Vandenabeele, P. & Krysko, D.V. Necroptosis: The release of damage-associated molecular patterns and its physiological relevance. Immunity 38, 209-223 (2013).
14. Kono, H. & Rock, K.L.How dying cells alert the immune system to danger. Nat. Rev. Immunol. 8, 279-289 (2008).
15. Krysko, O., Vandenabeele, P., Krysko, D.V. & Bachert, C. Impairment of phagocytosis of apoptotic cells and its role in chronic airway diseases. Apoptosis 15, 1137-1146 (2010).
16. Gallo, P.M. & Gallucci, S. The dendritic cell response to classic, emerging, and homeostatic danger signals. Implications for autoimmunity. Front. Immunol. 4, 138 (2013).
17. Kasahara, Y. et al. Endothelial cell death and decreased expression of vascular endothelial growth factor and vascular endothelial growth factor receptor 2 in emphysema. Am. J. Respir. Crit. Care Med. 163, 737-744 (2001).
18. Tuder, R.M. & Petrache, I. Pathogenesis of chronic obstructive pulmonary disease. J. Clin. Invest. 122, 2749-2755 (2012).
19. Van Der Toorn, M. et al. Cigarette smoke-induced blockade of the mitochondrial respiratory chain switches lung epithelial cell apoptosis into necrosis.Am. J. Physiol. Lung Cell.Mol. Physiol. 292, L1211-L1218 (2007).
20. Martin, S.J., Henry, C.M. & Cullen, S.P. A perspective on mammalian caspases as positive and negative regulators of inflammation. Mol. Cell 46, 387-397 (2012).
21. Hirsiger, S., Simmen, H.-P., Werner, C.M.L., Wanner, G.a. & Rittirsch, D. Danger signals activating the immune response after trauma. Mediators Inflamm. 2012, 315941 (2012).
22. Krysko, D.V. et al. Immunogenic cell death and DAMPs in cancer therapy. Nat. Rev. Cancer 12, 860-875 (2012).
23. Vanden Berghe, T. et al. Necrosis is associated with IL-6 production but apoptosis is not. Cell. Signal. 18, 328-335 (2006).
24. Chen, G.Y. & Nun+ ez, G. Sterile inflammation: Sensing and reacting to damage. Nat. Rev. Immunol. 10, 826-837 (2010).
25. Joly, A.-L., Wettstein, G.,Mignot,G., Ghiringhelli, F. & Garrido, C. Dual role of heat shock proteins as regulators of apoptosis and innate immunity. J. Innate Immun. 2, 238-247 (2010).
26. Multhoff, G. Heat shock protein 70 (Hsp70): Membrane location, export and immunological relevance. Methods 43, 229-237 (2007).
27. Asea, A., Kabingu, E., Stevenson, M.A. & Calderwood, S.K. HSP70 peptidembearing and peptide-negative preparations act as chaperokines. Cell Stress Chaperones 5, 425-431 (2000).
28. Tolle, L.B. & Standiford, T.J. Danger associated molecular patterns (DAMPs) in acute lung injury. J. Pathol. 229, 1-34 (2013).
29. Asea, A. et al. Novel signal transduction pathway utilized by extracellular HSP70: Role of toll-like receptor (TLR) 2 and TLR4. J. Biol. Chem. 277, 15028-15034 (2002).
30. Pinot, F., el Yaagoubi, A., Christie, P., Dinh-Xuan, A.T. & Polla, B.S. Induction of stress proteins by tobacco smoke in human monocytes: Modulation by antioxidants. Cell Stress Chaperones 2, 156-161 (1997).
31. Hacker, S. et al. Elevated HSP27, HSP70 and HSP90 alpha in chronic obstructive pulmonary disease: Markers for immune activation and tissue destruction. Clin. Lab. 55, 31-40 (2009).
32. Cappello, F. et al. Convergent sets of data from in vivo and in vitro methods point to an active role of hsp60 in chronic obstructive pulmonary disease pathogenesis. PLoS One 6, e28200 (2011).
33. Kreutmayer, S.B. et al. Dynamics of heat shock protein 60 in endothelial cells exposed to cigarette smoke extract. J. Mol. Cell. Cardiol. 51, 777-780 (2011).
34. Heizmann, C.W., Ackermann, G.E. & Galichet, A. Pathologies involving the S100 proteins and RAGE. Subcell. Biochem. 45, 93-138 (2007).
35. Edgeworth, J., Gorman, M., Bennett, R., Freemont, P. & Hogg, N. Identification of p8,14as a highly abundant heterodimeric calcium binding protein complex of myeloid cells. J. Biol. Chem. 266, 7706-7713 (1991).
36. Rammes, A. et al. Myeloid-related protein (MRP) 8 and MRP14, calciumbinding proteins of the S100 family, are secreted by activated monocytes via a novel, tubulin-dependent pathway. J. Biol. Chem. 272, 9496-9502 (1997).
37. Srikrishna, G. S100A8 and S100A9: New insights into their roles in malignancy. J. Innate Immun. 4, 31-40 (2012).
38. Merkel, D., Rist,W., Seither, P., Weith, A. & Lenter, M.C. Proteomic study of human bronchoalveolar lavage fluids from smokers with chronic obstructive pulmonary disease by combining surface-enhanced laser desorption/ionization-mass spectrometry profiling with mass spectrometric protein identification. Proteomics 5, 2972-2980 (2005).
39. Lorenz, E. et al. Different expression ratio of S100A8/A9 and S100A12 in acute and chronic lung diseases. Respir. Med. 102, 567-573 (2008).
40. Miniati, M. et al. Soluble receptor for advanced glycation end products in COPD: Relationship with emphysema and chronic cor pulmonale: A casecontrol study. Respir. Res. 12, 37 (2011).
41. Cockayne, D.a. et al. Systemic biomarkers of neutrophilic inflammation, tissue injury and repair in COPD patients with differing levels of disease severity. PLoS One 7, e38629 (2012).
42. Ferhani, N. et al. Expression of high-mobility group box 1 and of receptor for advanced glycation end products in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 181, 917-927 (2010).
43. Smith, D.J. et al. Reduced soluble receptor for advanced glycation endproducts in COPD. Eur. Respir. J. 37, 516-522 (2011).
44. Sukkar, M.B. et al. Soluble RAGE is deficient in neutrophilic asthma and COPD. Eur. Respir. J. 39, 721-729 (2012).
45. Sukkar,M.B. et al. RAGE: A new frontier in chronic airways disease. Br. J. Pharmacol., 1-37 (2012).
46. Hancock, D.B. et al. Meta-analyses of genome-wide association studies identify multiple loci associated with pulmonary function. Nat. Genet. 42, 45-52 (2010).
47. Repapi, E. et al. Genome-wide association study identifies five loci associated with lung function. Nat. Genet. 42, 36-44 (2010).
48. Liu, F.-T., Yang, R.-Y. & Hsu, D.K. Galectins in acute and chronic inflammation. Ann. NY Acad. Sci. 1253, 80-91 (2012).
49. Sato, S., St-Pierre, C., Bhaumik, P. & Nieminen, J. Galectins in innate immunity: Dual functions of host soluble beta-galactoside-binding lectins as damage-associated molecular patterns (DAMPs) and as receptors for pathogen-associated molecular patterns (PAMPs). Immunol. Rev. 230, 172-187 (2009).
50. Liu, F.-T. & Rabinovich, G.a. Galectins: Regulators of acute and chronic inflammation. Ann. NY Acad Sci. 1183, 158-182 (2010).
51. Bhaumik, P., St-Pierre, G., Milot, V., St-Pierre, C. & Sato, S. Galectin-3 facilitates neutrophil recruitment as an innate immune response to a parasitic protozoa cutaneous infection. J. Immunol. 190, 630-640 (2012).
52. Pilette, C. et al. Increased galectin-3 expression and intra-epithelial neutrophils in small airways in severe COPD. Eur. Respir. J. 29, 914-922 (2007).
53. Vega-Carrascal, I. et al. Dysregulation of TIM-3-galectin-9 pathway in the cystic fibrosis airways. J. Immunol. 186, 2897-2909 (2011).
54. Cederlund, A., Gudmundsson, G.H. & Agerberth, B. Antimicrobial peptides important in innate immunity. FEBS J. 278, 3942-3951 (2011).
55. Ganz, T. Defensins: Antimicrobial peptides of innate immunity. Nat. Rev. Immunol. 3, 710-720 (2003).
56. Rosin, D.L. & Okusa, M.D. Dangers within: DAMP responses to damage and cell death in kidney disease. J.Am. Soc.Nephrol. 22, 416-425 (2011).
57. Biragyn, A. et al. Murine beta-defensin 2 promotes TLR-4/MyD88-mediated and NF-kappaB-dependent atypical death of APCs via activation of TNFR2. J. Leukoc. Biol. 83, 998-1008 (2008).
58. Chaly, Y.V. et al. Neutrophil alpha-defensin human neutrophil peptide modulates cytokine production in human monocytes and adhesion molecule expression in endothelial cells. Eur.Cytokine Netw. 11, 257-266 (2000).
59. Yang, D., Chen, Q., Chertov, O. & Oppenheim, J.J. Human neutrophil defensins selectively chemoattract naive T and immature dendritic cells. J. Leukoc. Biol. 68, 9-14 (2000).
60. Van Wetering, S., Mannesse-Lazeroms, S.P.G., Van Sterkenburg, M.A.J.A. & Hiemstra, P.S. Neutrophil defensins stimulate the release of cytokines by airway epithelial cells: Modulation by dexamethasone. Inflamm. Res. 51, 8-15 (2002).
61. Paone, G. et al. Human neutrophil peptides sputum levels in symptomatic smokers and COPD patients. Eur. Rev. Med. Pharmacol. Sci. 15, 556-562 (2011).
62. Andresen, E.,Gu+nther,G., Bullwinkel, J., Lange, C. & Heine, H. Increased expression of beta-defensin 1 (DEFB1) in chronic obstructive pulmonary disease. PLoS One 6, e21898 (2011).
63. Pace, E. et al. TLR4 upregulation underpins airway neutrophilia in smokers with chronic obstructive pulmonary disease and acute respiratory failure. Hum. Immunol. 72, 54-62 (2011).
64. Tsoumakidou, M., Bouloukaki, I., Thimaki, K., Tzanakis, N. & Siafakas, N.M. Innate immunity proteins in chronic obstructive pulmonary disease and idiopathic pulmonary fibrosis. Exp. Lung Res. 36, 373-380 (2010).
65. Chen, L. et al. Cigarette smoke enhances {beta}-defensin 2 expression in rat airways via nuclear factor-{kappa}B activation. Eur. Respir. J. 36, 638-645 (2010).
66. Garcha, D.S. et al. Changes in prevalence and load of airway bacteria using quantitative PCR in stable and exacerbated COPD. Thorax 67, 1075-1080 (2012).
67. Almansa, R. et al. Viral infection is associated with an increased proinflammatory response in chronic obstructive pulmonary disease. Viral Immunol. 25, 249-253 (2012).
68. Zanetti, M., Gennaro, R. & Romeo, D. Cathelicidins: A novel protein family with a common proregion and a variable C-terminal antimicrobial domain. FEBS Lett. 374, 1-5 (1995).
69. Cowland, J.B., Johnsen, A.H. & Borregaard, N. hCAP-18, a cathelin/probactenecin-like protein of human neutrophil specific granules. FEBS Lett. 368, 173-176 (1995).
70. Bals, R. et al. The peptide antibiotic LL-37/hCAP-18 is expressed in epithelia of the human lung where it has broad antimicrobial activity at the airway surface. Proc. Natl. Acad. Sci. USA 95, 9541-9546 (1998).
71. Agerberth, B. et al. Antibacterial components in bronchoalveolar lavage fluid from healthy individuals and sarcoidosis patients. Am. J. Respir. Crit. Care Med. 160, 283-290 (1999).
72. Zaiou, M. & Gallo, R.L. Cathelicidins, essential gene-encoded mammalian antibiotics. J. Mol. Med. 80, 549-561 (2002).
73. Takeuchi, O. & Akira, S. Pattern recognition receptors and inflammation. Cell 140, 805-820 (2010).
74. Zhang, J. et al. Novel sulfated polysaccharides disrupt cathelicidins, inhibit RAGE and reduce cutaneous inflammation in a mouse model of rosacea. PLoS One 6, e16658 (2011).
75. Tjabringa,G.S., Ninaber, D.K., Drijfhout, J.W., Rabe, K.F. &Hiemstra, P.S. Human cathelicidin LL-37 is a chemoattractant for eosinophils and neutrophils that acts via formyl-peptide receptors. Int. Arch. Allergy Immunol. 140, 103-112 (2006).
76. Shaykhiev, R. et al. Human endogenous antibiotic LL-37 stimulates airway epithelial cell proliferation and wound closure. Am. J. Physiol. 289, L842-L848 (2005)
77. Jiang, Y.-Y. et al. The effect of human antibacterial peptide LL-37 in the pathogenesis of chronic obstructive pulmonary disease. Respir. Med. 106, 1680-1689 (2012).
78. Parameswaran, G.I., Sethi, S. & Murphy, T.F. Effects of bacterial infection on airway antimicrobial peptides and proteins in COPD. Chest 140, 611-617 (2011).
79. Xiao, W., Hsu, Y.-P., Ishizaka, A., Kirikae, T. & Moss, R.B. Sputum cathelicidin, urokinase plasminogen activation system components, and cytokines discriminate cystic fibrosis, COPD, and asthma inflammation. Chest 128, 2316-2326 (2005).
80. Golec, M. et al. Cathelicidin LL-37 in bronchoalveolar lavage and epithelial lining fluids from COPD patients and healthy individuals. J. Biol. Regul. Homeost. Agents 26, 617-625 (2012).
81. Sims, G.P., Rowe, D.C., Rietdijk, S.T., Herbst, R. & Coyle, A.J. HMGB1 and RAGE in inflammation and cancer. Annu. Rev. Immunol. 28, 367-388 (2010).
82. Andersson, U. et al. High mobility group 1 protein (HMG-1) stimulates proinflammatory cytokine synthesis in human monocytes. J. Exp. Med. 192, 565-570 (2000).
83. Bell, C.W., Jiang, W., Reich, C.F. & Pisetsky, D.S. The extracellular release of HMGB1 during apoptotic cell death. Am. J. Physiol. 291, C1318-C1325 (2006).
84. Gardella, S. et al. The nuclear protein HMGB1 is secreted by monocytes via a non-classical, vesicle-mediated secretory pathway. EMBO Rep. 3, 995-1001 (2002).
85. Kokkola, R. et al. RAGE is the major receptor for the proinflammatory activity of HMGB1 in rodent macrophages. Scand. J. Immunol. 61, 1-9 (2005).
86. Park, J.S. et al. Involvement of toll-like receptors 2 and 4 in cellular activation by high mobility group box 1 protein. J. Biol. Chem. 279, 7370-7377 (2004).
87. Lippai, D. et al. Alcohol-induced IL-1b in the brain is mediated by NLRP3/ ASC inflammasome activation that amplifies neuroinflammation. J. Leukoc. Biol. 94, 171-182 (2013).
88. Bianchi, M.E. HMGB1 loves company. J. Leukoc. Biol. 86, 573-576 (2009).
89. Hreggvidsdottir, H.S. et al. The alarmin HMGB1 acts in synergy with endogenous and exogenous danger signals to promote inflammation. J. Leukoc. Biol. 86, 655-662 (2009).
90. Bianchi, M.E. DAMPs, PAMPs and alarmins: All we need to know about danger. J. Leukoc. Biol. 81, 1-5 (2007).
91. Dumitriu, I.E., Baruah, P., Bianchi, M.E.,Manfredi, A.A. & Rovere-Querini, P. Requirement of HMGB1 and RAGE for the maturation of human plasmacytoid dendritic cells. Eur. J. Immunol. 35, 2184-2190 (2005).
92. Yanai, H., Ban, T. & Taniguchi, T. High-mobility group box family of proteins: Ligand and sensor for innate immunity. Trends Immunol. 33, 633-640 (2012).
93. Rouhiainen, A., Tumova, S., Valmu, L., Kalkkinen, N. & Rauvala, H. Pivotal advance: Analysis of proinflammatory activity of highly purified eukaryotic recombinant HMGB1 (amphoterin). J. Leukoc. Biol. 81, 49-58 (2007).
94. Pisetsky, D. Cell death in the pathogenesis of immune-mediated diseases: The role of HMGB1 and DAMP-PAMP complexes. Swiss Med. Wkly. 141, w13256 (2011).
95. Venereau, E. et al. Mutually exclusive redox forms of HMGB1 promote cell recruitment or proinflammatory cytokine release. J. Exp. Med. 209, 1519-1528 (2012).
96. Tadie, J-M. et al. HMGB1 promotes neutrophil extracellular trap formation through interactions with Toll-like receptor. Am. J. Physiol. 304, L342-L349 (2013).
97. Wood, A.M., de Pablo, P., Buckley, C.D., Ahmad, A. & Stockley, R.A. Smoke exposure as a determinant of autoantibody titre in a1-antitrypsin deficiency and COPD. Eur. Respir. J. 37, 32-38 (2011).
98. Hou, C. et al. High mobility group protein B1 (HMGB1) in asthma: Comparison of patients with chronic obstructive pulmonary disease and healthy controls. Mol. Med. 17, 807-815 (2011).
99. Kanazawa, H. et al. Validity of HMGB1 measurement in epithelial lining fluid in patients with COPD. Eur. J. Clin. Invest. 42, 419-426 (2011).
100. Bezerra, F.S. et al. Long-term exposure to cigarette smoke impairs lung function and increases HMGB-1 expression in mice. Respir. Physiol. Neurobiol. 177, 120-126 (2011).
101. Saiwichai, T. et al. Green tea extract supplement inhibition of HMGB1 release in rats exposed to cigarette smoke. Southeast Asian J. Trop. Med. Public Health 41, 250-258 (2010).
102. Garg, A.D. et al. Immunogenic cell death, DAMPs and anticancer therapeutics: An emerging amalgamation. Biochim. Biophys. Acta 1805, 53-71 (2010).
103. Garg, A.D. et al. A novel pathway combining calreticulin exposure and ATP secretion in immunogenic cancer cell death. EMBO J. 31, 1062-1079 (2012).
104. Kepp, O. et al. Immunogenic cell death modalities and their impact on cancer treatment. Apoptosis 14, 364-375 (2009).
105. Gardai, S.J. et al. Cell-surface calreticulin initiates clearance of viable or apoptotic cells through trans-activation of LRP on the phagocyte. Cell 123, 321-334 (2005).
106. Somborac-Bacura, A. et al. Cigarette smoke induces endoplasmic reticulum stress response and proteasomal dysfunction in human alveolar epithelial cells. Exp. Physiol. 98, 316-325 (2013).
107. Jorgensen, E. et al. Cigarette smoke induces endoplasmic reticulum stress and the unfolded protein response in normal and malignant human lung cells. BMC Cancer 8, 229 (2008).
108. Malhotra, D. et al. Heightened endoplasmic reticulum stress in the lungs of patients with chronic obstructive pulmonary disease: The role of Nrf2-regulated proteasomal activity. Am. J. Respir. Crit. Care Med. 180, 1196-1207 (2009).
109. Ribeiro, C.M.P. & O+Neal, W.K. Endoplasmic reticulum stress in chronic obstructive lung diseases. Curr. Mol. Med. 12, 872-882 (2012).
110. Kelsen, S.G. et al. Cigarette smoke induces an unfolded protein response in the human lung: A proteomic approach. Am. J. Respir. Cell Mol. Biol. 38, 541-550 (2008).
111. Krysko, D.V. et al. Emerging role of damage-associated molecular patterns derived frommitochondria in inflammation. Trends Immunol. 32, 157-164 (2011).
112. Schwacha, M.G., Rani, M., Zhang, Q., Nunez-Cantu, O. & Cap, A.P. Mitochondrial damage-associated molecular patterns activate gd T-cells. Innate Immun. (2013; e-pub ahead of print).
113. Sun, S. et al. Mitochondrial DAMPs increase endothelial permeability through neutrophil dependent and independent pathways. PLoS One 8, e59989 (2013).
114. Gray, M.W. Mitochondrial evolution. Cold Spring Harb. Perspect. Biol. 4, a011403 (2012).
115. Collins, L.V. et al. Endogenously oxidized mitochondrial DNA induces in vivo and in vitro inflammatory responses. J. Leukoc. Biol. 75, 995-1000 (2004).
116. Krieg, A.M. The role of CpG motifs in innate immunity. Curr. Opin. Immunol. 12, 35-43 (2000).
117. Zhang, Q. et al. Circulating mitochondrial DAMPs cause inflammatory responses to injury. Nature 464, 104-107 (2010).
118. Schiffmann, E. et al. The isolation and partial characterization of neutrophil chemotactic factors from Escherichia coli. J. Immunol. 114, 1831-1837 (1975).
119. Schiffmann, E., Corcoran, B.A. &Wahl, S.M. N-formylmethionyl peptides as chemoattractants for leucocytes. Proc. Natl. Acad. Sci. USA 72, 1059-1062 (1975).
120. Carp, H. Mitochondrial N-formylmethionyl proteins as chemoattractants for neutrophils. J. Exp. Med. 155, 264-275 (1982).
121. Migeotte, I., Communi, D. & Parmentier, M. Formyl peptide receptors: A promiscuous subfamily of G protein-coupled receptors controlling immune responses. Cytokine Growth Factor Rev. 17, 501-519 (2006).
122. Boulay, F., Tardif, M., Brouchon, L. & Vignais, P. The human N-formylpeptide receptor.Characterization of two cDNA isolates and evidence for a new subfamily of G-protein-coupled receptors. Biochemistry 29, 11123-11133 (1990).
123. Raoof, M., Zhang, Q., Itagaki, K. & Hauser, C.J. Mitochondrial peptides are potent immune activators that activate human neutrophils via FPR-1. J. Trauma 68, 1328-1332. discussion 1332-4 (2010).
124. McDonald, B. et al. Intravascular danger signals guide neutrophils to sites of sterile inflammation. Science 330, 362-366 (2010).
125. Atzori, L. et al. Absence of proteinase-activated receptor-1 signaling in mice confers protection from fMLP-induced goblet cell metaplasia. Am. J. Respir. Cell Mol. Biol. 41, 680-687 (2009).
126. Cardini, S. et al. Genetic ablation of the fpr1 gene confers protection from smoking-induced lung emphysema in mice. Am. J. Respir. Cell Mol. Biol. 47, 332-339 (2012).
127. Matheson, M., Rynell, A.-C., McClean, M. & Berend, N. Cigarette smoking increases neutrophil formyl methionyl leucyl phenylalanine receptor numbers. Chest 123, 1642-1646 (2003).
128. Ghiringhelli, F. et al. Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors. Nat. Med. 15, 1170-1178 (2009).
129. Mortaz, E., Folkerts, G., Nijkamp, F.P. & Henricks, P.a.J. ATP and the pathogenesis of COPD. Eur. J. Pharmacol. 638, 1-4 (2010).
130. Chen, Y. et al. ATP release guides neutrophil chemotaxis via P2Y2 and A3 receptors. Science 314, 1792-1795 (2006).
131. Lommatzsch, M. et al. Extracellular adenosine triphosphate and chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 181, 928-934 (2010).
132. Ferrari, D. et al. Extracellular ATP triggers IL-1 beta release by activating the purinergic P2Z receptor of human macrophages. J. Immunol. 159, 1451-1458 (1997).
133. Mortaz, E. et al. ATP in the pathogenesis of lung emphysema. Eur. J. Pharmacol. 619, 92-96 (2009).
134. Lucattelli, M. et al. P2-7 receptor signaling in the pathogenesis of smoke-induced lung inflammation and emphysema. Am. J. Respir. Cell Mol. Biol. 44, 423-429 (2011).
135. Cicko, S. et al. Purinergic receptor inhibition prevents the development of smoke-induced lung injury and emphysema. J. Immunol. 185, 688-697 (2010).
136. Sorice,M. et al. Cardiolipin and its metabolites move frommitochondria to other cellular membranes during death receptor-mediated apoptosis. Cell Death Differ. 11, 1133-1145 (2004).
137. Lusuardi, M. et al. Role of surfactant in chronic obstructive pulmonary disease: Therapeutic implications. Respiration 59 (Suppl 1), 28-32 (1992).
138. Van Crombruggen, K., Jacob, F., Zhang, N. & Bachert, C. Damageassociated molecular patterns and their receptors in upper airway pathologies. Cell. Mol. Life Sci. (2013; e-pub ahead of print).
139. Hallgren, O. et al. Altered fibroblast proteoglycan production in COPD. Respir. Res. 11, 55 (2010).
140. Merrilees, M.J. et al. Changes in elastin, elastin binding protein and versican in alveoli in chronic obstructive pulmonary disease. Respir. Res. 9, 41 (2008).
141. Annoni, R. et al. Extracellular matrix composition in chronic obstructive pulmonary disease. Eur. Respir. J. 40, 1362-1373 (2012).
142. Krimmer, D.I., Burgess, J.K., Wooi, T.K., Black, J.L. & Oliver, B.G.G. Matrix proteins from smoke-exposed fibroblasts are pro-proliferative. Am. J. Respir. Cell Mol. Biol. 46, 34-39 (2012).
143. Kranenburg, A.R. et al. Enhanced bronchial expression of extracellular matrix proteins in chronic obstructive pulmonary disease. Am. J. Clin. Pathol. 126, 725-735 (2006).
144. Bracke, K.R. et al. Enhanced deposition of low-molecular-weight hyaluronan in lungs of cigarette smoke-exposed mice. Am. J. Respir. Cell Mol. Biol. 42, 753-761 (2010).
145. Dentener, M.A., Vernooy, J.H.J., Hendriks, S. & Wouters, E.F.M. Enhanced levels of hyaluronan in lungs of patients with COPD: Relationship with lung function and local inflammation. Thorax 60, 114-119 (2005).
146. Cho, Y., McQuade, T., Zhang, H., Zhang, J. & Chan, F.K.-M. RIP1-dependent and independent effects of necrostatin-1 in necrosis and Tcell activation. PLoS One 6, e23209 (2011).
147. Doz, E. et al. Cigarette smoke-induced pulmonary inflammation is TLR4/MyD88 and IL-1R1/MyD88 signaling dependent. J. Immunol. 180, 1169-1178 (2008).
148. Maes, T., Bracke, K.R., Joos, G.F. & Brusselle, G.G. Comment on +Cigarette smoke-induced pulmonary inflammation is TLR4/MyD88 and IL-1R1/MyD88 signaling dependent+. J. Immunol. 180, 5761 (2008).